Nanobody Discovery Service for CAR-T and Cell Therapy Development

Successful CAR-oriented nanobody discovery requires more than simple target binding. Candidate binders must recognize native cell-surface antigens, exhibit suitable affinity profiles, maintain functional activity in CAR formats, and minimize off-target interactions.

To address these challenges, our discovery workflows integrate membrane protein-focused immunization strategies, cell-based screening, and quantitative display technologies to enable efficient identification of CAR-compatible nanobody candidates.

Why Nanobodies for CAR Development?

Compact and Modular Architecture

The small VHH format enables efficient CAR construction and flexible multi-specific engineering.

Reduced Aggregation Risk

Compared with scFvs, nanobodies generally show lower aggregation tendencies, helping reduce tonic signaling risk.

Excellent Membrane Protein Recognition

Nanobodies are highly suitable for recognizing native membrane proteins and conformational epitopes.

Compatibility with Advanced CAR Designs

Supports dual-target, tandem, and logic-gated CAR architectures.

Our CAR-Oriented Nanobody Discovery Strategy

Our workflows are specifically optimized for CAR and cell therapy applications, with a focus on membrane protein targeting, epitope selection, and downstream CAR compatibility.

Key considerations include:

Membrane Protein-Focused Discovery

Cell-surface antigen recognition

Epitope-Focused Screening

Minimization of off-target binding

Discovery Workflow Options

Immunization-Based Workflow

Camelid immunization → PBMC isolation → Library construction → Binder screening → Validation(Optional)

Recommended for therapeutic CAR development programs requiring high-diversity and suitable-affinity binders.

Premade Library Workflow

Premade library selection → Binder screening → Validation(Optional)

Recommended for rapid target validation and early-stage exploratory programs.

Deliverables

Clients will receive:

CAR-suitable nanobody sequences

Candidate binder analysis report

Expression-ready constructs (optional)

Binding validation data (optional)

Comprehensive project report

Optional downstream services:

Nanobody humanization

Affinity maturation

Typical Project Timeline

Option 1 — Immunization-Based Discovery

Stage	Deliverables	Timeline
Immunization	Serum titer report	8 weeks
Library construction	Immune phage or yeast display library	3–4 weeks
Library screening	Enriched CAR-oriented binders	4-6 weeks
Optional candidate production	Purified VHH and expression-ready constructs	2–3 weeks
Optional validation	Binding and functional assay data	2–4 weeks

Typical total timeline:

Approximately 15-18 weeks depending on project complexity and screening strategy.

Option 2 — Premade Library Screening

Stage	Deliverables	Timeline
Library screening	Enriched CAR-oriented binder sequences	4-6 weeks
Optional candidate production	Purified VHH or expression-ready constructs	2–3 weeks
Optional validation	Binding and functional assay data	2–4 weeks

Typical total timeline:

Approximately 4–13 weeks depending on validation requirements.

Advantages of Our CAR-T Target Nanobody Discovery Platform

Successful CAR-T target nanobody discovery requires binders that recognize native cell-surface antigens and maintain suitable binding characteristics in the final CAR architecture. NBbiolab combines camelid immunization, VHH library construction, cell-based screening, and advanced display technologies to identify nanobody candidates for CAR-T and other cell therapy development programs.

Native Cell-Surface Antigen Recognition

CAR targeting depends on the recognition of antigens presented on the surface of target cells. Our discovery strategies incorporate membrane protein-focused immunization and cell-based screening to help identify VHH candidates that recognize native cell-surface structures rather than relying exclusively on isolated recombinant proteins.

Epitope-Focused Binder Selection

The location and accessibility of an antigen epitope can influence CAR recognition and downstream receptor activity. Our screening strategies consider target accessibility, epitope characteristics, and potential off-target interactions when selecting candidates for further evaluation.

Affinity Profile Optimization

Higher binding affinity does not always translate into better CAR-T performance. Depending on target expression patterns and therapeutic objectives, an appropriately tuned affinity profile may help balance tumor recognition and potential off-tumor activity. Candidate selection can therefore consider both binding strength and target-dependent functional requirements.

Flexible Phage and Yeast Display Platforms

Different antigen formats require different screening technologies. Phage display supports target-specific enrichment, including cell-based screening against native membrane proteins, while yeast display enables quantitative FACS-based evaluation and affinity-focused selection using suitable recombinant antigens.

CAR-Compatible Candidate Evaluation

Beyond initial antigen binding, selected VHH candidates can be evaluated for specificity, cross-reactivity, sequence properties, and other characteristics relevant to downstream CAR development. Optional validation can be discussed according to the target and project objectives.

CAR-T Target Nanobody Discovery: Target Selection Considerations

Target selection is a critical step in CAR-T nanobody development. An appropriate target should provide accessible cell-surface epitopes, a relevant expression profile, and sufficient distinction between disease-associated cells and normal tissues. These factors influence both the discovery strategy and the subsequent evaluation of candidate VHH binders.

Common Target Categories in CAR-T Research

Target Category	Representative Antigens	Key Discovery Considerations
B-Cell Lineage Antigens	CD19, CD20	Cell-surface expression, antigen specificity, and recognition of target-positive B-cell populations.
Multiple Myeloma-Associated Antigens	BCMA, GPRC5D	Target expression on malignant plasma cells, antigen accessibility, and potential antigen heterogeneity.
Solid Tumor-Associated Antigens	Mesothelin, HER2, GPC3	Tumor-associated expression, normal tissue distribution, and accessible extracellular epitopes.
Other Cell-Surface Targets	Project-specific membrane proteins and receptors	Target structure, antigen availability, expression profile, and screening feasibility.

These examples represent target categories relevant to CAR-T research. The feasibility of each discovery project depends on antigen availability, target biology, and the required screening and validation strategy.

Antigen Expression and Tumor Selectivity

Target expression levels can influence CAR recognition and cellular activation. A target with heterogeneous expression may require additional evaluation of antigen density and recognition thresholds. Comparing target-positive cells with relevant negative or normal-cell controls can help assess potential off-target recognition.

Epitope Accessibility and CAR Architecture

The epitope recognized by a VHH binder can influence how the antigen-binding domain interacts with its target in a CAR construct. Epitope accessibility, membrane proximity, antigen orientation, and the selected spacer and hinge configuration should be considered during downstream CAR design. These factors may affect receptor engagement and cellular responses.

Antigen Heterogeneity and Escape Risk

Antigen expression may vary among tumor cells and change during disease progression or treatment. For selected projects, evaluating target expression across different cell populations and considering dual-target or tandem CAR strategies can help inform the broader cell therapy development plan.

Key Evaluation Criteria for CAR-Compatible Nanobody Candidates

Identifying a positive antigen-binding clone is only the initial stage of CAR-T target nanobody discovery. Candidates should undergo further evaluation to determine whether their binding properties, epitope characteristics, and molecular features are suitable for the intended CAR application.

1. Native Cell-Surface Binding

Candidates should be assessed for their ability to recognize antigens in their native cell-surface context. Cell-based binding assays using target-expressing cells can help distinguish binders that recognize physiologically relevant membrane structures from those that bind only isolated recombinant antigen formats.

2. Binding Affinity and Kinetics

Binding affinity and association or dissociation characteristics can influence antigen recognition and receptor engagement. The optimal affinity depends on target expression, epitope accessibility, and the intended CAR design. Extremely strong binding is not necessarily ideal for every CAR-T application, particularly when tumor selectivity is an important consideration.

3. Epitope Recognition

Epitope characteristics can influence antigen accessibility and CAR engagement. Where required, candidate comparison can consider epitope location, recognition of different antigen regions, and potential competition with endogenous ligands or other binding molecules.

4. Specificity and Cross-Reactivity

Specificity evaluation helps reduce the risk of unintended recognition of unrelated proteins or normal cells. Depending on project requirements, counter-screening may involve target-negative cell lines, homologous proteins, related antigens, and relevant species variants.

5. Sequence Developability

VHH sequence characteristics can influence recombinant expression, stability, aggregation tendency, and downstream engineering. Sequence analysis and candidate expression studies can help prioritize molecules with suitable properties for subsequent CAR construct development.

6. Functional Compatibility in CAR Formats

A nanobody that binds a purified antigen or target-expressing cell does not automatically guarantee effective CAR activity. Where included in the project scope, further evaluation in the intended CAR format can investigate surface expression, antigen-dependent activation, and target-cell recognition. Functional assessment should be performed using suitable CAR construct and cellular assay systems.

Important: Initial VHH screening and CAR-T functional validation are different experimental stages. The standard discovery deliverables focus on nanobody candidates and their agreed characterization. CAR construct engineering, T-cell transduction, cytotoxicity testing, and advanced cell therapy development should be separately defined in the project scope.

Nanobody Screening for Cell Therapy: Phage Display vs. Yeast Display

The choice of display technology depends on antigen format, target structure, and the intended downstream CAR application. For cell therapy nanobody development, screening against native cell-surface antigens is particularly important when the final CAR is designed to recognize membrane-associated targets.

Comparison	Phage Display	Yeast Display
Antigen Compatibility	Recombinant proteins, peptides, and target-expressing cells.	Primarily suitable purified recombinant proteins and compatible antigens.
Cell-Based Screening	Suitable for cell-based biopanning and native cell-surface antigen selection.	Primarily used for fluorescence-based screening with labeled antigens.
Screening Strategy	Iterative target binding, washing, enrichment, and clone selection.	MACS and FACS-based enrichment and selection.
Main Advantages	Flexible antigen presentation and native cell-surface target screening.	Quantitative binding evaluation and affinity-focused selection.
Typical CAR-T Application	Initial discovery against native membrane and cell-surface targets.	Quantitative candidate comparison and affinity optimization when compatible antigens are available.

For most projects targeting native membrane proteins, cell-based phage display screening is a suitable initial strategy because it allows target recognition to be evaluated in a cellular context. Yeast display can complement this approach when quantitative binding analysis or affinity optimization is required using an appropriate antigen format.

Learn more about our Phage Display Nanobody Discovery Service and Yeast Display VHH Discovery Service to understand the screening technologies available for different nanobody discovery projects.

CAR-T Target Nanobody Discovery Case Studies

Real project experience is important when evaluating a nanobody discovery partner. NBbiolab has conducted target-specific VHH discovery projects involving GPRC5D and CD20, two cell-surface antigens relevant to cellular immunotherapy research. These projects demonstrate the use of camelid immunization, immune library construction, cell-based screening, and candidate validation.

Case Study 1: GPRC5D Nanobody Discovery

Multiple Myeloma Target Cell-Based Immunization Phage Display

GPRC5D is a cell-surface receptor of the GPCR family and an important therapeutic target in multiple myeloma research. Its expression on malignant plasma cells makes it relevant to GPRC5D-directed cellular immunotherapy and bispecific antibody development.

The project aimed to identify GPRC5D-specific VHH candidates using an alpaca immunization strategy with GPRC5D-overexpressing cells as the immunogen.

Discovery and Screening Process

One alpaca was immunized with GPRC5D-overexpressing cells over a 49-day program.
Serum titers reached 1:1,000, with FACS signals exceeding three times the negative control.
An immune phage display library with more than 1 × 10⁹ independent clones was constructed.
The library achieved a 100% insert-positive rate.
270 monoclonal clones were screened and analyzed.

Project Results

14 unique GPRC5D-specific VHH sequences were identified.
13 candidates were confirmed as GPRC5D-specific binders.
Candidate sequence properties and molecular characteristics were analyzed.
Monoclonal screening and recombinant VHH validation supported candidate identification.

This project demonstrates how cell-based immunization and high-diversity immune library screening can support the discovery of nanobody candidates against challenging cell-surface targets for CAR-oriented research.

Case Study 2: CD20 Nanobody Discovery

B-Cell Surface Antigen Cross-Species Binding Cell-Based Validation

CD20 is a well-established B-cell surface antigen and a relevant target in B-cell malignancy research. This project focused on discovering VHH candidates capable of recognizing human and cynomolgus CD20 and binding to CD20-positive tumor cells.

Discovery and Screening Process

One alpaca was immunized with CD20-overexpressing cells for 49 days.
Serum titers reached 1:1,000, with FACS signals exceeding three times the negative control.
An immune phage display library with more than 1 × 10⁹ independent clones was constructed.
The library achieved a 100% insert-positive rate.
Three rounds of cell-based biopanning were performed with counter-selection and CD20-positive selection.
270 monoclonal clones were screened.

Project Results

9 unique VHH sequences were identified.
8 candidates were confirmed as CD20-specific binders.
Cell-based binding activity was evaluated against human CD20-positive cell models.
Cross-species binding was assessed using cynomolgus CD20-expressing cells.
Representative candidate BS092-12 demonstrated EC₅₀ values of 6.068 nM against human CD20-expressing CHOK1 cells and 5.252 nM against cynomolgus CD20-GFP-HEK293 cells.

This project demonstrates the application of cell-based screening, cross-species evaluation, and recombinant VHH characterization in the discovery of cell-surface target binders.

Scientific note: The reported CD20 project demonstrated target-specific cell-surface binding and cross-species recognition. CD20 does not undergo significant internalization upon antibody binding according to the project report. These results support nanobody discovery for cell-surface targeting research but should not be interpreted as evidence of internalization or completed CAR-T functional validation. The reported EC₅₀ values are cell-based assay measurements, not direct kinetic affinity (K_D) measurements.

Information Required for Cell Therapy Nanobody Development

A well-defined project brief helps establish the appropriate discovery strategy and evaluation criteria. Before starting a CAR-T target nanobody discovery project, clients are encouraged to provide the following information.

Project Information	Details to Provide	Purpose
Target Antigen	Target protein name, gene name, amino acid sequence, or UniProt ID.	Identifies the target and supports initial project feasibility assessment.
Target Species	Human, mouse, cynomolgus monkey, or other relevant species.	Defines cross-species recognition requirements.
Antigen Format	Recombinant protein, extracellular domain, target-expressing cells, or other available formats.	Supports antigen preparation and screening platform selection.
Target Expression	Expression levels, positive cell lines, and available negative controls.	Helps assess cell-surface recognition and target selectivity.
Desired Binder Properties	Binding affinity, specificity, epitope accessibility, and cross-reactivity requirements.	Defines the desired candidate profile.
CAR Design Requirements	Single-target, tandem, dual-target, or other CAR architecture, if already determined.	Helps consider antigen-binding domain requirements during candidate selection.
Downstream Evaluation	VHH expression, binding validation, CAR-format assessment, or functional studies.	Defines optional downstream characterization requirements.

If the CAR architecture or desired binding characteristics have not yet been finalized, clients can initially provide the target antigen and research objectives. The screening strategy can then be discussed according to the available materials and intended development stage.

From Nanobody Discovery to Cell Therapy Development

Identifying a suitable VHH sequence is an important milestone, but further development may be required before a candidate can be evaluated in a CAR-based cellular system. Depending on project objectives, selected nanobodies can proceed through recombinant production, molecular engineering, and additional functional characterization.

Recombinant Nanobody Expression and Purification

Selected VHH sequences can be transferred into suitable expression constructs for recombinant protein production. Purified nanobodies can then be evaluated for identity, purity, binding activity, and other agreed quality attributes. Explore our Nanobody Expression & Production service for downstream recombinant VHH production.

Additional Engineering and Optimization

Depending on the desired application, selected candidates may require further sequence optimization, affinity tuning, or humanization. These activities should be designed around the target biology, candidate characteristics, and intended CAR architecture.

CAR Construct and Functional Evaluation

After binder selection, the VHH sequence can be incorporated into a suitable CAR design for subsequent research. Evaluation may include CAR surface expression, antigen-dependent activation, target-cell recognition, and cytotoxicity testing, depending on the agreed development scope.

The nanobody discovery service and full CAR-T cell product development are distinct project scopes. CAR vector engineering, T-cell modification, cell expansion, potency assessment, and GMP manufacturing should be separately specified when required.

Frequently Asked Questions About CAR-T Target Nanobody Discovery

1. What is CAR-T target nanobody discovery?

CAR-T target nanobody discovery is a process for identifying VHH binders against selected cell-surface antigens for use as antigen-recognition domains in chimeric antigen receptor designs. The process may involve camelid immunization, VHH library construction, display-based screening, cell-based binding evaluation, and candidate characterization.

2. Why are nanobodies used in CAR-T cell therapy development?

Nanobodies are compact single-domain antibody fragments that can offer favorable stability and modular engineering properties. Their relatively small size can support the design of compact antigen-recognition domains and multi-specific CAR architectures. Their suitability for a particular CAR application still requires evaluation of binding, specificity, expression, and functional performance.

3. Which targets can be considered for CAR-T nanobody screening?

Potential targets include B-cell antigens such as CD19 and CD20, multiple myeloma-associated antigens such as BCMA and GPRC5D, and selected solid tumor-associated cell-surface proteins. Target feasibility depends on antigen availability, expression characteristics, membrane accessibility, and project-specific screening requirements.

4. Which display platform is more suitable for CAR-T target nanobody discovery?

Phage display is generally suitable for initial discovery against native cell-surface antigens, especially when cell-based screening is important. Yeast display is useful for quantitative binding analysis and affinity-focused selection using compatible recombinant antigens. The platform should be selected according to target format and the desired screening outcome.

5. What affinity is preferred for CAR-T nanobody candidates?

There is no single affinity value suitable for every CAR-T application. The preferred binding profile depends on target density, antigen distribution, epitope accessibility, and therapeutic objectives. Moderate-affinity binders may be preferable in certain situations where reducing recognition of low-antigen-density normal cells is important. Candidate selection should consider affinity together with specificity and CAR-format functional performance.

6. How do you reduce off-target binding during CAR-T nanobody screening?

Screening specificity can be improved through counter-selection against negative cell lines, evaluation against related antigens, and cell-based binding validation. Additional cross-reactivity studies can help identify unwanted interactions before candidates are considered for downstream development.

7. What validation assays are available for CAR-oriented nanobody candidates?

Depending on project requirements, optional characterization may include cell-surface binding assays, cross-reactivity assessment, binding affinity analysis, internalization studies where biologically relevant, and basic functional evaluation. CAR-specific activation and cytotoxicity assays require an appropriate CAR construct and cellular assay system and should be separately defined in the project scope.

8. Can selected nanobodies be further optimized for CAR-T applications?

Yes. Selected VHH candidates may undergo additional affinity maturation, humanization, recombinant expression, and other engineering activities according to their intended application. Further optimization should consider both molecular developability and the functional requirements of the final CAR design.

9. Does nanobody discovery include complete CAR-T cell manufacturing?

No. Nanobody discovery primarily focuses on identifying and characterizing antigen-binding VHH candidates. CAR construct engineering, T-cell transduction, cell expansion, functional potency testing, and GMP cell manufacturing are separate development activities and are not automatically included in the standard nanobody discovery service.

Advantages of Our CAR Nanobody Discovery Platform

Discovery strategies optimized for CAR applications

Strong expertise in membrane protein targeting

Integrated phage and yeast display platforms

Cell-based screening capability

FAQs

Can your platform support membrane protein and cell-surface antigen discovery?

Yes. Our workflows are specifically optimized for native membrane protein recognition using:

● Cell-based immunization and screening strategies

● Cell-surface binding validation

● Functional display technologies

● Epitope-focused selection approaches

This helps enrich binders that recognize physiologically relevant antigen conformations.

Do you provide both immunization-based and synthetic/premade library workflows?

Yes. We offer:

● Immunization-based discovery for therapeutic programs requiring high diversity and affinity maturation potential

● Premade library screening for rapid exploratory or early validation projects

We can also help recommend the most suitable strategy based on timeline, target complexity, and development stage.

What affinity range is typically preferred for CAR applications?

The optimal affinity depends on the target biology and therapeutic strategy. Extremely high affinity is not always ideal for CAR-T applications. In many cases, moderate affinity binders may improve tumor selectivity and reduce off-tumor activity. Our screening workflows can be adjusted to support affinity tuning objectives.

Which workflow is better for therapeutic CAR development?

For most therapeutic CAR-T programs, immunization-based workflows are generally preferred because they often generate higher-diversity repertoires, better epitope coverage, more naturally matured binders, and improved developability profiles. Premade libraries are often suitable for rapid feasibility studies or early-stage target validation.

Can you screen for binders recognizing native cell-surface antigens instead of recombinant proteins only?

Yes. This is a major focus of our CAR-oriented discovery strategy. This helps reduce the risk of identifying binders that fail in CAR cellular contexts.

For CAR-oriented VHH discovery, phage display or yeast display—which is more suitable, and what should be considered?

Selection depends on antigen format and required native conformation relevance for CAR function.

Phage display is generally preferred for CAR-target discovery against cell-surface or membrane proteins, especially when:

● Native membrane conformation is critical

● Recombinant proteins may not reflect physiological structure

● Cell-based or native antigen screening is required

Many membrane targets differ between recombinant and cell-surface forms, so phage-based cell screening better preserves CAR-relevant epitope context.

Yeast display is more suitable for:

● Purified recombinant protein screening

● Well-folded, structurally stable antigens

● Affinity maturation or quantitative binding optimization

It is generally less ideal for direct cell-based selection due to larger cell size and higher background in cell-sorting assays, which can reduce specificity resolution.

Practical selection guideline

● Phage display best for native membrane/cell-based, CAR-relevant epitope discovery

● Yeast display best for recombinant protein systems and downstream affinity optimization

In CAR nanobody discovery, platform choice should prioritize how closely the screening antigen mimics the final cell-surface CAR target context.

How do you minimize off-target binding risk?

We incorporate several risk-reduction strategies, including:

● Counter-screening against negative cell lines

● Specificity-focused selection workflows

● Epitope-focused screening

● Cell-based validation assays

Optional downstream characterization can further evaluate specificity profiles.

What validation assays can be included?

Optional validation services may include:

● Cell-surface binding assays

● Cross-reactivity assessment

● Internalization analysis

● Basic functional characterization

Validation scope can be customized based on project requirements.